Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors

Hongxiang Lan, Curtiss J. DuRand, Martha M. Teeter and Kim A. Neve
Molecular Pharmacology January 2006, 69 (1) 185-194; DOI: https://doi.org/10.1124/mol.105.017244
Hongxiang Lan
Departments of Behavioral Neuroscience (K.A.N.) and Physiology and Pharmacology (H.L.), Oregon Health and Science University, and Veterans Affairs Medical Center (K.A.N.), Portland, Oregon; Department of Chemistry, University of California, Davis, California (M.M.T.); Department of Chemistry, Boston College, Chestnut Hill, Massachusetts (M.M.T.); and Department of Psychiatry, University of California Medical Center, Sacramento, California (C.J.D., M.M.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Curtiss J. DuRand
Departments of Behavioral Neuroscience (K.A.N.) and Physiology and Pharmacology (H.L.), Oregon Health and Science University, and Veterans Affairs Medical Center (K.A.N.), Portland, Oregon; Department of Chemistry, University of California, Davis, California (M.M.T.); Department of Chemistry, Boston College, Chestnut Hill, Massachusetts (M.M.T.); and Department of Psychiatry, University of California Medical Center, Sacramento, California (C.J.D., M.M.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martha M. Teeter
Departments of Behavioral Neuroscience (K.A.N.) and Physiology and Pharmacology (H.L.), Oregon Health and Science University, and Veterans Affairs Medical Center (K.A.N.), Portland, Oregon; Department of Chemistry, University of California, Davis, California (M.M.T.); Department of Chemistry, Boston College, Chestnut Hill, Massachusetts (M.M.T.); and Department of Psychiatry, University of California Medical Center, Sacramento, California (C.J.D., M.M.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim A. Neve
Departments of Behavioral Neuroscience (K.A.N.) and Physiology and Pharmacology (H.L.), Oregon Health and Science University, and Veterans Affairs Medical Center (K.A.N.), Portland, Oregon; Department of Chemistry, University of California, Davis, California (M.M.T.); Department of Chemistry, Boston College, Chestnut Hill, Massachusetts (M.M.T.); and Department of Psychiatry, University of California Medical Center, Sacramento, California (C.J.D., M.M.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

To test the hypothesis that pharmacological differentiation between D1 and D2 dopamine receptors results from interactions of selective ligands with nonconserved residues lining the binding pocket, we mutated amino acid residues in the D2 receptor to the corresponding aligned residues in the D1 receptor and vice versa and expressed the receptors in human embryonic kidney 293 cells. Determinations of the affinity of the 14 mutant D2 receptors and 11 mutant D1 receptors for D1- and D2-selective antagonists, and rhodopsin-based homology models of the two receptors, identified two residues whose direct interactions with certain ligands probably contribute to ligand selectivity. The D1 receptor mutant W993.28F showed dramatically increased affinity for several D2-selective antagonists, particularly spiperone (225-fold), whereas the D2 receptor mutant Y4177.43W had greatly decreased affinity for benzamide ligands such as raclopride (200-fold) and sulpiride (125-fold). The binding of the D1-selective ligand R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390) was unaffected, indicating that SCH23390 makes little contact with these ancillary pocket residues. Mutation of A/V5.39 caused modest but consistent and reciprocal changes in affinity of the receptors for D1 and D2-selective ligands, perhaps reflecting altered packing of the interface of helices 5 and 6. We also obtained some evidence that residues in the second extracellular loop contribute to ligand binding. We conclude that additional determinants of D1/D2 receptor-selective binding are located either in that loop or in the transmembrane helices but, like residue 5.39, indirectly influence the interactions of selective ligands with conserved residues by altering the shape of the primary and ancillary binding pockets.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 69 (1)
Molecular Pharmacology
Vol. 69, Issue 1
1 Jan 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors

Hongxiang Lan, Curtiss J. DuRand, Martha M. Teeter and Kim A. Neve
Molecular Pharmacology January 1, 2006, 69 (1) 185-194; DOI: https://doi.org/10.1124/mol.105.017244

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors

Hongxiang Lan, Curtiss J. DuRand, Martha M. Teeter and Kim A. Neve
Molecular Pharmacology January 1, 2006, 69 (1) 185-194; DOI: https://doi.org/10.1124/mol.105.017244
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • GABAAR Molecular Identity in Oligodendrocytes
  • Editing TOP2α Intron-19 5′ SS Circumvents Drug Resistance
  • SerpinA3N and drug induced liver injury
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics